Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Sigma Healthcare Ltd (ASX:SIG) Shares Leap Higher On API Takeover Rejection

Today Sigma Healthcare Ltd (ASX: SIG) shares jumped nearly 5% after it reported its full-year results for the period ending 31 January 2019, citing $100 million in efficiency gains as it reasserts the rejection of a takeover proposal by Australian Pharmaceutical Industries Ltd (ASX: API).

Sigma is a pharmacy distribution business and the name behind Amcal, Chemist King, Discount Drug Stores, Guardian and PharmaSave. In 2018, Sigma announced it would lose its contract to supply Chemist Warehouse. However, it remains a multi-million-dollar company with chemists dotted throughout the country.

Key Results

Sigma reported:

  • Revenue down 2.9% to $3.98 billion
  • EBITDA down 17.5% to $76.5 million
  • Net profit after tax (NPAT) down 33.1% to $37 million
  • A final dividend of 2 cents per share (cps) fully franked at a payout ratio of 101.5%.

Sigma cited sales in the low margin Hepatitis C medicines as being down $226 million as the major reason for its revenue decline.  Hepatitis C medicine sales also impacted its EBITDA and NPAT, along with restructuring costs.

Chemist Warehouse, Savings, Share Buybacks

After the company’s contract with Chemist Warehouse comes to an end in June 2019, the company expects to be able to free up working capital and deliver $100 million in efficiency gains over the next two years. It expects part of the savings to come directly from ceasing the delivery of services to Chemist Warehouse and additional savings from cost restructures.

Sigma also said it has not bought back any shares in the financial year ended, but “it remains a live option looking forward”.

Rejection of API Takeover

API made a non-binding indicative proposal to Sigma in December 2018 offering 0.31 API shares and $0.23 cash for every Sigma share, implying a value of $0.686 per Sigma share at the time. A key part of this offer was the $60 million in synergies,

However, in March 2019 Sigma received a revised offer with a waiver of the condition precedent relating to confirmation of cost synergies. Sigma Healthcare has now decided such a takeover is not in the best interests of shareholders.

Outlook

The company has guided for $55-60 million EBITDA in FY20 with CEO and Managing Director, Mark Hooper saying, “We are confident … [in savings] over $100 million, but just as importantly [we] will free up capacity for growth. Our investment program is well advanced to provide the physical capacity for growth, and by FY20 our Balance Sheet will have financial headroom for growth.

[ls_content_block id=”14947″ para=”paragraphs”]

Disclaimer: At the time of writing, Andrew does not own shares in any of the companies mentioned.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Skip to content